- Report
- October 2024
- 188 Pages
Global
From €3371EUR$3,545USD£2,834GBP
€3745EUR$3,939USD£3,149GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1189EUR$1,250USD£999GBP
- Report
- May 2024
- 135 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Report
- May 2024
- 128 Pages
Global
From €6179EUR$6,499USD£5,196GBP
- Report
- June 2024
- 200 Pages
Global
From €7559EUR$7,950USD£6,356GBP
- Report
- June 2024
- 200 Pages
Global
From €7559EUR$7,950USD£6,356GBP
- Clinical Trials
- February 2024
- 60 Pages
Global
From €1189EUR$1,250USD£999GBP
- Report
- January 2022
- 60 Pages
Global
From €3756EUR$3,950USD£3,158GBP
- Report
- January 2022
- 60 Pages
Global
From €3756EUR$3,950USD£3,158GBP
- Report
- February 2024
- 180 Pages
Global
From €4725EUR$4,969USD£3,973GBP
Dyspepsia is a condition characterized by upper abdominal pain, bloating, and nausea. Dyspepsia drugs are used to treat the symptoms of dyspepsia, as well as other gastrointestinal disorders. These drugs are typically divided into two categories: antacids and proton pump inhibitors (PPIs). Antacids are used to neutralize stomach acid and reduce symptoms of heartburn and indigestion. PPIs are used to reduce the amount of acid produced in the stomach, which can help reduce symptoms of acid reflux and ulcers.
The dyspepsia drug market is a subset of the larger gastrointestinal drug market. This market is driven by the increasing prevalence of gastrointestinal disorders, such as irritable bowel syndrome, gastroesophageal reflux disease, and peptic ulcer disease. Additionally, the rising demand for over-the-counter medications and the increasing availability of generic drugs are expected to drive the growth of the dyspepsia drug market.
Some companies in the dyspepsia drug market include Pfizer, GlaxoSmithKline, AstraZeneca, Merck, and Novartis. Show Less Read more